Tools, trends, and technologies: analytics development in ADCs

Thursday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Tools, trends, and technologies: analytics development in ADCs

As ADCs continue to evolve in complexity, robust and fit-for-purpose analytical strategies have become central to successful development. From preclinical through clinical development to commercial manufacturing, analytics underpin critical decisions around product characterization, quality, safety, and comparability. However, the structural heterogeneity of ADCs - spanning conjugation chemistry, payload diversity, and linker design - presents unique and ongoing analytical challenges.

This expert panel-based webinar will examine the current landscape of analytical development for ADCs, focusing on the tools, trends, and emerging technologies shaping best practices across the product lifecycle. Experts will discuss how advances in mass spectrometry, bioanalytical methods, imaging, and functional assays are enabling deeper molecular understanding, improved control strategies, and more efficient development pathways.

The discussion will also explore how analytical approaches are adapting alongside next-generation ADC formats, and how data integration and methodological innovation are supporting greater confidence in product characterization and performance.

Attend this webinar to:

Gain insight into the analytical challenges specific to ADC structure, heterogeneity, and stability
Explore current and emerging tools used to characterize conjugation, payload distribution, and critical quality attributes
Learn how analytical strategies evolve from discovery through clinical development and manufacturing
Understand how novel ADC formats are influencing analytical requirements and method development

Luying Yang

Senior Scientist and Analytics Group Lead at Zymeworks

Luying Yang has over eight years of experience in the biotech industry, specializing in the ADC and antibody characterization from early-stage discovery to development. With a strong foundation in method development and method optimization, she brings a unique, cross-functional perspective to the analytical challenges of complex modalities such as ADCs. She is passsionate about bridging the gap between research and CMC, focusing on robust analytical characterization, method ruggedness, and seamless tech transfer.

Wei-Han Lee

TechOp Lead and Senior Director at OBI Pharma

Wei-Han Lee serves as the TechOp Lead and Senior Director at OBI Pharma, where he spearheads the analytical and CMC development of the company’s next-generation ADC portfolio. With a Ph.D. in Chemistry from National Taiwan University, he is an expert in analytical chemistry and mass spectrometry, specializing in the characterization and quality control of complex biologics. Since 2017, he has been instrumental in advancing multiple ADC clinical projects, bridging the gap between candidate selection and IND submission.

His leadership focuses on the precision analysis of site-specific conjugation technology and the establishment of robust analytical platforms for novel linkers and payloads. Drawing on over a decade of industry experience, he manages complex CMC transitions, including site transfers and process scale-up, while ensuring rigorous method validation. By integrating mass spectrometry and advanced chromatography, he ensures the stability and comparability of OBI’s innovative ADC pipeline for global clinical advancement.

Eef Dirksen

Director of Analytical Development and Quality Control at Byondis

Eef Dirksen is an analytical expert in pharmaceutical CMC development of monoclonal antibodies and antibody-based therapeutic molecules, with over 15 years of experience in the field. Originally trained as a protein mass spectrometrist, he has evolved into a trusted analytical specialist supporting a wide range of development activities for antibodies and ADCs. Eef's expertise spans developability and manufacturability assessments, GMP release testing, stability and comparability studies, as well as extended characterization of complex biologics. Driven by curiosity about the complexity of protein-based biotherapeutics, he contributed to several regulatory filings across both early- and late-stage programs, including Keytruda (Merck/MSD) and SYD985 (vic-trastuzumab duocarmazine, Byondis).